Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.
The company reported earnings and the shares have rolled over and turned down.
Let's check out the charts and indicators of both NovoCure and Zai Lab.
The shares rallied nicely in December.
The company's charts simply aren't showing sustained strength.
Let's dip into the biotech mailbag as the year comes to an end.
PFE is fundamentally sound and certainly not overvalued.
Here's what traders should do now.
Here's a booster for my May Dynavax Technologies trade.
The charts of this ETF have upside promise, thanks in part to a number of its larger holdings displaying positive-looking charts.